论文部分内容阅读
上周,美国食品和药品管理局(FDA)的一个专家组建议 FDA 应向医生和患者发出有关药物洗脱冠状动脉支架的警告。除低危的患者以外,药物洗脱支架的安全性仍不清楚。再者,患者置入药物洗脱支架后应该应用抗血小板药物治疗至少持续到置人术后一年。经皮冠状动脉介入治疗是冠心病患者的主要治疗方法。2005年,英国这项治疗的例数是73 000例,而冠状动脉旁路移植术的数量仅25 000例。药
Last week, a panel of experts from the U.S. Food and Drug Administration (FDA) advised the FDA to warn doctors and patients about drug-eluting coronary stents. In addition to low-risk patients, the safety of drug-eluting stents remains unclear. In addition, patients should be treated with antiplatelet drugs for at least one year after placement in the drug eluting stent. Percutaneous coronary intervention is the main treatment of patients with coronary heart disease. In 2005, the number of cases treated in the United Kingdom was 73 000, compared to 25 000 for coronary artery bypass grafting. medicine